Revolution Contraceptives received a $200,000 grant from the Male Contraceptive Initiative (MCI) to advance Vasalgel towards human trials. The grant will support preclinical studies that will evaluate contraceptive effectiveness, procedural simplicity, reversibility, and safety. This proof-of-concept study will build on results from earlier preclinical studies and should support a future application for clinical trials in men.
“MCI’s generous support will increase our ability to provide men with a revolutionary new birth control option,” said Revolution Contraceptives CEO Edward Gillis.
See the full press release here.
